BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11281957)

  • 1. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.
    Heresco-Levy U; Javitt DC; Ermilov M; Silipo G; Shimoni J
    Int J Neuropsychopharmacol; 1998 Dec; 1(2):131-135. PubMed ID: 11281957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of D-cycloserine on negative symptoms in schizophrenia.
    Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
    Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
    van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
    Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
    Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.
    Heresco-Levy U; Javitt DC; Gelfin Y; Gorelik E; Bar M; Blanaru M; Kremer I
    J Affect Disord; 2006 Jul; 93(1-3):239-43. PubMed ID: 16677714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
    Heresco-Levy U; Gelfin G; Bloch B; Levin R; Edelman S; Javitt DC; Kremer I
    Int J Neuropsychopharmacol; 2013 Apr; 16(3):501-6. PubMed ID: 23174090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
    Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
    Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    Heresco-Levy U; Javitt DC; Ermilov M; Mordel C; Horowitz A; Kelly D
    Br J Psychiatry; 1996 Nov; 169(5):610-7. PubMed ID: 8932891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
    Heresco-Levy U; Javitt DC
    Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder.
    Heresco-Levy U; Kremer I; Javitt DC; Goichman R; Reshef A; Blanaru M; Cohen T
    Int J Neuropsychopharmacol; 2002 Dec; 5(4):301-7. PubMed ID: 12466030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
    Goff DC; Tsai G; Manoach DS; Coyle JT
    Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
    Goff DC; Herz L; Posever T; Shih V; Tsai G; Henderson DC; Freudenreich O; Evins AE; Yovel I; Zhang H; Schoenfeld D
    Psychopharmacology (Berl); 2005 Apr; 179(1):144-50. PubMed ID: 15502972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.
    Goff DC
    Curr Neuropharmacol; 2017; 15(1):21-34. PubMed ID: 26915421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-serine added to clozapine for the treatment of schizophrenia.
    Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
    Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia.
    Rosse RB; Fay-McCarthy M; Kendrick K; Davis RE; Deutsch SI
    Clin Neuropharmacol; 1996 Oct; 19(5):444-50. PubMed ID: 8889288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.